| Annual · values | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -7.32 M CAD | -4.89 M CAD | -6.64 M CAD | -12.28 M CAD | -13.66 M CAD | -4.99 M CAD | — | -1.29 M CAD | -4.70 M CAD | -4.51 M CAD | -4.41 M CAD | -4.27 M CAD |
| Depreciation & Amortization | 119273 CAD | 186049 CAD | 183471 CAD | 118188 CAD | 118788 CAD | 57563 CAD | — | 1655 CAD | 179322 CAD | 149565 CAD | 159521 CAD | 158313 CAD |
| Stock-Based Compensation | 729642 CAD | 537492 CAD | 1.25 M CAD | 2.26 M CAD | 3.20 M CAD | 598359 CAD | — | 154313 CAD | 115546 CAD | 259379 CAD | 267222 CAD | 956634 CAD |
| Capital Expenditures | — | — | 0 CAD | 5656 CAD | 6146 CAD | 4856 CAD | — | 6869 CAD | 302733 CAD | 402271 CAD | 274589 CAD | 279065 CAD |
| Cash Flow from Investing | — | — | 0 CAD | -5656 CAD | -6146 CAD | 19073 CAD | — | -4.47 M CAD | 1.69 M CAD | 557411 CAD | 122470 CAD | -741415 CAD |
| Cash Flow from Financing | 17.03 M CAD | 592031 CAD | 4.83 M CAD | 11.63 M CAD | 14.17 M CAD | 7.09 M CAD | — | 8.77 M CAD | 0 CAD | 7.31 M CAD | 106777 CAD | 10.79 M CAD |
| Dividends Paid | — | — | — | — | — | — | — | — | — | — | — | — |
| Stock Buybacks | — | — | — | — | — | — | — | — | — | — | — | — |
| Free Cash Flow | — | — | -6.64 M CAD | -12.28 M CAD | -13.67 M CAD | -4.99 M CAD | — | -1.30 M CAD | -5.00 M CAD | -4.91 M CAD | -4.69 M CAD | -4.55 M CAD |
Edesa Biotech Inc. is a clinical-stage pharmaceutical company focused on the development and commercialization of innovative therapies for dermatological and gastrointestinal indications. The company's primary purpose is to address unmet medical needs by leveraging its proprietary research and extensive clinical expertise to create novel treatment options. Edesa Biotech Inc. specializes in small molecule drugs and biologics, targeting conditions where existing therapies are inadequate or non-existent. Notably, the company's pipeline includes potential treatments for atopic dermatitis and allergic contact dermatitis, aiming to improve patient outcomes in skin health. Situated in a competitive biotech industry, Edesa Biotech plays a significant role by contributing to medical advancement and potential breakthrough treatments in dermatology. Through its dedication to clinical trials and regulatory approvals, Edesa Biotech strives to enhance its market position and impact healthcare practices worldwide.